TP53-Specific Mutations Serve as a Potential Biomarker for Homologous Recombination Deficiency in Breast Cancer: A Clinical Next-Generation Sequencing Study

Medicine, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology, Genetics,
next-generation sequencing   homologous recombination deficiency   TP53   breast cancer   biomarker  

Breast cancer is one of the most common malignant tumors among women worldwide, with a complex pathogenesis involving multiple gene mutations and signaling pathway abnormalities. Homologous Recombination Deficiency (HRD) is a significant molecular characteristic in breast cancer, closely related to patients’ sensitivity to PARP inhibitor (PARPi) th...

Patterns of Genomic Instability in Ovarian Cancer Patients

Medicine, Obstetrics and Gynecology, Oncology, Life Sciences, Biochemistry, Genetics,
ovarian cancer   genomic instability   PARP inhibitors   homologous recombination deficiency   clinical trials   BRCA mutations   precision medicine  

Background and Research Question Ovarian cancer, as a fatal gynecological malignancy, has become the focus of recent studies, particularly on expanding the feasibility of targeted therapies. The introduction of poly(ADP-ribose) polymerase (PARP) inhibitors has marked a groundbreaking treatment option for ovarian cancer, especially for patients with...